Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0BE8H
|
|||
Drug Name |
INCB62079
|
|||
Indication | Liver cancer [ICD-11: 2C12; ICD-10: C22] | Phase 1/2 | [1] | |
Company |
Incyte Wilmington, DE
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Fibroblast growth factor receptor 4 (FGFR4) | Target Info | Inhibitor | [1] |
KEGG Pathway | MAPK signaling pathway | |||
Ras signaling pathway | ||||
Rap1 signaling pathway | ||||
Endocytosis | ||||
PI3K-Akt signaling pathway | ||||
Signaling pathways regulating pluripotency of stem cells | ||||
Regulation of actin cytoskeleton | ||||
Panther Pathway | FGF signaling pathway | |||
Pathway Interaction Database | FGF signaling pathway | |||
Reactome | PI3K Cascade | |||
PIP3 activates AKT signaling | ||||
FGFR4 ligand binding and activation | ||||
Constitutive Signaling by Aberrant PI3K in Cancer | ||||
Phospholipase C-mediated cascade | ||||
FRS-mediated FGFR4 signaling | ||||
SHC-mediated cascade:FGFR4 | ||||
PI-3K cascade:FGFR4 | ||||
Negative regulation of FGFR4 signaling | ||||
RAF/MAP kinase cascade | ||||
WikiPathways | Regulation of Actin Cytoskeleton | |||
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | ||||
PIP3 activates AKT signaling | ||||
Signaling by FGFR |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.